Explore published screening research, the rationale for structured VR practice, and the status of rehabilitation studies. Screening performance, training outcomes and regulatory records answer different questions.
Research supports informed questions, not guaranteed outcomes. Independent studies are not LumiBrain-specific validation. Assessment modules, home training, certificates and patents have different purposes and scopes.
A 2024 study evaluated VR Eye-tracking Cognitive Assessment (VECA) in 201 participants in Shenzhen. A machine-learning model predicted MoCA scores from gaze-based tasks. The reported correlation was r=0.90; sensitivity was 88.5% and specificity 83% for the study’s cognitive-impairment classification.
Read the study ↗r=0.90 is a correlation coefficient—not “90% diagnostic accuracy.” This was an adult screening study, not a trial of home rehabilitation or LumiBrain, and external validation is still needed.
A 2024 Shenzhen community study used 823 older-adult records to develop machine-learning screening models from accessible health and AD8-related information. It supports the company’s broader screening research context; it did not test a VR headset or rehabilitation treatment.
Read the study ↗Oyama and colleagues examined rapid eye-tracking cognitive assessment in 2019. This is foundational work on gaze-based cognitive measurement, rather than a QuickMind product trial.
Read the study ↗A three-arm trial in 90 children with ADHD compared VR social-skills training, traditional training and a waitlist. Some social-skill and parent-rated outcomes improved, while cooperation and inhibition did not differ significantly between groups. This was not a LumiBrain trial.
Read the study ↗An open-label trial in 78 preschool children with ASD studied a nonwearable VR-CBT programme added to an existing intervention. Some behavioural and sensory outcomes improved; the language subscale did not show a significant effect. Its nonwearable technology and population differ from LumiBrain.
Read the study ↗Company materials describe ongoing VR rehabilitation work involving Shenzhen People’s Hospital and the Second Affiliated Hospital of Guangzhou Medical University, with MoCA follow-up. A full protocol, cohort description and peer-reviewed rehabilitation results were not supplied. We therefore do not present the brochure’s “≈20% improvement” as a verified home-use outcome or promise.
Sources: company About supplement (pp. 3–5, 19–21), QuickMind brochure and supplied product sheets. Published research is linked directly below.
U.S. PATENTUS 11,977,679 B1View document ↗
EU DECLARATIONVR Cognitive · Class IView document ↗
U.S. DOCUMENTFDA registration & listingView document ↗
EXPORT CERTIFICATEMedical product export certificateView document ↗
THAILAND69-2-3-2-0005652View document ↗
HONG KONGMDACS Listing 261055View document ↗
MALAYSIAGA9442926-244979View document ↗Patent protection, conformity declarations and regional listings each have a different scope; none is a promise of an individual outcome.
Documents refer to specific models and regions. The supplied U.S. record is an establishment registration and device listing, not evidence of 510(k) clearance. No LumiBrain-specific clearance is asserted here.